Body identical micronised progesterone greatly reduces the oestrogen induced risk of endometrial cancer in women with an intact uterus1,2,3 Safety & tolerability

Safety & Tolerability

For a full list of adverse events please refer to the Summary of Product Characteristics.1
HRT is associated with an increased risk of venous thromboembolism (VTE), however unlike other progestogens, there is no significant association of VTE with micronised progesterone1,26,27,28
In women taking oestrogen plus micronised progesterone, there was no significantly increased risk of breast cancer associated with short durations of use (≤ 5 years)*, when HRT was initiated ≤ 3 years of menopause29
Utrogestan (micronised progesterone) 100mg contains soya lecithin. As there is a possible relationship between allergy to soya and allergy to peanut, people with soya or peanut allergy should avoid using this medicine. For the avoidance of doubt, Utrogestan 100mg does not contain peanut products.1

* Longer duration of use (> 5 years) was associated with statistically significant increase in breast cancer risk for all types of oestrogen – progesterone with the exception of oestrogen + dydrogesterone


1. Utrogestan Summary of Product Characteristics. Available from Last accessed: April 2021.
2. Panay N, Post Reprod Health 2014;20(2):69-72.
3. Fournier A, et al. Am J Epidemiol. 2014;180(5):508-517.
26. Canonico M, et al. Circulation 2007;115:840-845.
27. Canonico M, et al. Arterioscler Thromb Vasc Biol. 2010;30:340-345.
28. Scarabin P, Climacteric 2018;21(4):341-345.
29. Fournier A, et al. J Clin Oncol 2009;27(31):5138–5143.